Navigation Links
Amsterdam Molecular Therapeutics Reports Half Year Results 2008
Date:8/13/2008

Conference Call & Webcast Today at 2:00 p.m. CET

AMSTERDAM, August 13 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the first half year of 2008.

Highlights

- Positive results of pivotal trial for Glybera(R) (AMT-011)

for Hyperlipoproteinemia type I

- European patent for treatment of Non-Alcoholic Steatotic

Hepatitis

- License for treatment of Duchenne Muscular Dystrophy from La

Sapienza University, Rome, Italy

- License for prevention of immune response against treatment of

Hemophilia B from 'TIGET", San Raffaele Telethon Gene Therapy Institute,

Milan, Italy

- Collaboration with St. Jude Children's Research Hospital,

Memphis, Tennessee, USA, including license for treatment of Hemophilia B

- GMP manufacturing development: License for raising yields of

production platform from NIH, Bethesda, USA

- Key financial figures in line with guidance

- Cash & cash equivalents of EUR 43.1 million at June 30, 2008

- Independent supervisory board with three new members bringing

extensive knowledge and experience.

Results comparison

AMT's key financial figures are in line with the guidance that the company has given for 2008. The operating loss increased to EUR 9.1 million for the six months ended June 30, 2008, from EUR 7.2 million for the same period in 2007. This difference is primarily due to the increase of research & development costs to EUR 5.8 million from EUR 3.8 million in the same period of 2007. This increase is particularly related to the development work on the company's lead product Glybera(R) (AMT-011) and increased staffing for this and other programs. General and administrative costs decreased slightly to EUR 3.3 million from EUR 3.5 million for the same period in 2007 due to lower share-based payments.


'/>"/>
SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amsterdam Molecular Therapeutics Part of Next Biotech Index
2. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
3. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
4. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
5. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
6. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
7. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
8. Molecular Biometrics Announces Results of Parkinsons Disease Research and Receipt of Grant From Michael J. Fox Foundation to Advance Diagnostic Technology
9. Dr. George Poste Named Non-Executive Vice Chairman of CDX Holdings, Parent of Caris Diagnostics and Caris Molecular Diagnostics
10. New Turbomolecular Pumping System From Varian, Inc. Delivers Portable, Dry, Ultra-high Vacuum.
11. Xceed Molecular to Launch New Inflammation Xpress Chip(TM)for the Ziplex(R) Automated Gene-Expression Analysis System at Clinical Lab Expo 2008, Booth 2155
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... PMG Research, Inc. announced today ... a network of sites that provide clinical research services to ... patient lives through its partnerships with large physician practices and ... site locations in the Southeastern United States and spans over ... board will be held by: Dr. Robert Holmes, ...
(Date:11/26/2014)... Continuing its award-winning streak, Nerium International, the leader ... for outstanding creative achievement by its marketing and communication ... organization’s top honor, in the Branding category for its ... of this year. The event showcased top speakers and ... awarded a Gold MarCom Award in the Special Events ...
(Date:11/26/2014)... MA (PRWEB) November 26, 2014 ... collaboration company is proud to announce that Darren Suders ... and Sales. Darren will drive the partner ... positive customer experience. , Darren brings more ... has held key roles in channel operations, from policy ...
(Date:11/26/2014)... Bio-Techne Corporation (NASDAQ: TECH ) ... to serve in a newly created position of ... Gavin will be responsible for managing the operations of ... business acquired in July 2014 and the recently acquired ... -based ProteinSimple develops and commercializes proprietary systems and ...
Breaking Biology Technology:PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2SoundConnect Appoints Director of Channel Development & Sales 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3
... ,, A review of products for signal ... Activation of Signal Transduction Pathways with,PathDetect ... Mary Buchanan Chao-Feng Zheng ,Stratagene , ... such as,growth, differentiation, and coordination of cellular activities. ...
... streamlined and reliable method to obtain high-quality ... Basehore ,Stratagene , The StrataPrep ... quick, and reliable purification of bacteriophage single-stranded ... phage lysate exceeds the yield,obtained with the ...
... Preadipocytes and Differentiated Adipocytes ,,, A ... , Yuan-Di C. Halvorsen ,Zen-Bio, Inc. , ... , Regis Saladin , Ligand Pharmaceuticals ... , Stratagene introduces new tools to facilitate ...
Cached Biology Technology:Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 2Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 3Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 4Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 5Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 6Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 7Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 8Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 9Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 10Purified Single-Stranded M13 DNA for Automated Sequencing 2Purified Single-Stranded M13 DNA for Automated Sequencing 3Human Primary Preadipocytes and Differentiated Adipocytes 2Human Primary Preadipocytes and Differentiated Adipocytes 3Human Primary Preadipocytes and Differentiated Adipocytes 4Human Primary Preadipocytes and Differentiated Adipocytes 5Human Primary Preadipocytes and Differentiated Adipocytes 6
(Date:11/3/2014)... and preterm birth are linked to increased risk for ... the American College of Rheumatology (ACR) journal, Arthritis ... and pre-term babies were not at greater risk of ... According to the ACR, 27 million Americans over the ... of OA range from mild to severe and include ...
(Date:11/2/2014)... 2014)—In support of a bold quest to rid the ... Foundation today announced an award of US$156 million to ... in building new vaccines that will interrupt the cycle ... to zero" agenda. Such vaccines would ensure that parasite ... an "immunological bed net." , This approach to ...
(Date:11/2/2014)... and bump into a biologist . . . , While ... sketch, researchers have taken this premise and applied it to ... in the rising oceans of genomic data. , In this ... studies are publishing at a dizzying rate. The challenge is ... the noise (and there is no shortage of noise). , ...
Breaking Biology News(10 mins):Preterm, low birth-weight babies may need new hips in adulthood 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4Mutant models 2Mutant models 3Mutant models 4
... have believed that eating large amounts of protein made it ... the winner of five consecutive Olympic wrestling championships in the ... he built his crushing strength in part by consuming 20 ... go to such extremes, but Milo,s legacy survives in the ...
... cells, which make up 45 percent of blood, normally take ... side. But they can sometimes deform into an asymmetrical slipper ... explore how fluid flow might be responsible for this deformation, ... flow. The insights could help understand the mechanisms involved in ...
... 26, 2009 Results of an important new study ... at the time of cataract surgery increases a nutritional ... the development and/or progression of age-related macular degeneration (AMD). ... from the Macular Pigment Research Group at the Waterford ...
Cached Biology News:Moderate amounts of protein per meal found best for building muscle 2Blue light-filtering increases macular pigment, may protect against age-related vision loss 2Blue light-filtering increases macular pigment, may protect against age-related vision loss 3Blue light-filtering increases macular pigment, may protect against age-related vision loss 4